VCA Stocks

Dicerna Pharmaceuticals, Inc., an RNA interference company developing novel therapeutics utilizing proprietary Dicer Substrate Technology, today announced a second closing of its Series A financing, receiving a total of $8.4 million in additional venture capital.  Dicerna announced its strategic focus in the therapeutic areas of oncology, metabolic diseases and hepatitis C infection (HCV).  “Dicerna’s platform opens a second doorway into the RNAi space, distinct from current approaches in terms of both biological pathway and intellectual property,” stated Doug Fambrough, Ph.D., of Oxford Bioscience Partners, and co-founder and chairman of Dicerna. “Dicer Substrates represent a second generation of RNAi technology with greater potency, longer duration of action and enhanced potential for facilitated delivery, making previously undruggable targets accessible.”